Coherus BioSciences Provides Update on ‘619 IPR Institution Decision
September 07 2017 - 11:57AM
Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that the
Patent Trial and Appeal Board (“PTAB”) of the United States Patent
and Trademark Office denied institution of all four of its
petitions for Inter Partes Review (“IPR”) of AbbVie’s U.S. Patent
9,085,619 (“the ‘619 Patent”) related to AbbVie’s HUMIRA
(adalimumab) formulation.
“While we are disappointed by this outcome, we continue to
develop and refine our legal strategies for addressing any patents,
including formulation patents, that AbbVie may assert in District
Court proceedings,” said Denny Lanfear, President and Chief
Executive Officer of Coherus.
About Coherus BioSciences, Inc.Coherus is a
leading pure-play, global biosimilar company that develops and
commercializes high-quality therapeutics for major regulated
markets. Biosimilars are intended for use in place of existing,
branded biologics to treat a range of chronic and often
life-threatening diseases, with the potential to reduce costs and
expand patient access. Composed of a team of proven industry
veterans with world-class expertise in process science, analytical
characterization, protein production, sales & marketing and
clinical-regulatory development, Coherus is positioned as a leader
in the global biosimilar marketplace. Coherus is advancing three
late-stage clinical products towards commercialization, CHS-1701
(pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and
CHS-1420 (adalimumab biosimilar), as well as developing a robust
pipeline of future products in four therapeutic areas, oncology,
immunology (anti-TNF), ophthalmology and multiple sclerosis. For
additional information, please visit www.coherus.com.
Forward-Looking StatementsExcept for the
historical information contained herein, the matters set forth in
this press release, including statements regarding Coherus’ plans,
potential opportunities, expectations, projections, goals,
objectives, milestones, strategies, product pipeline, product
development, release of data and the potential benefits of its
products under development are forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including Coherus’
expectations regarding its ability to advance its intellectual
strategy for CHS-1420 including a final decision nullifying the
‘135 Patent, to complete CHS-1420 development and to initiate
CHS-1420 commercialization. Such forward-looking statements involve
substantial risks and uncertainties that could cause our clinical
development programs, future results, performance or achievements
to differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the uncertainties inherent in the clinical drug
development process, including the regulatory approval process, the
timing of our regulatory filings and other matters that could
affect the availability or commercial potential of our biosimilar
drug candidates, as well as possible patent litigation. Coherus
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Coherus’ business in general, see Coherus’ Quarterly
Report on Form 10-Q for the quarter ended June 30, 2017, filed with
the Securities and Exchange Commission on August 7, 2017 and its
future periodic reports to be filed with the Securities and
Exchange Commission.
HUMIRA® is a registered trademark of AbbVie Biotechnology, Ltd.
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
pobrien@coherus.com
+1 (650) 649-3527
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Sep 2023 to Sep 2024